Carmeli Yehuda, Eliopoulos George M, Samore Matthew H
Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Emerg Infect Dis. 2002 Aug;8(8):802-7. doi: 10.3201/eid0808.010418.
We conducted a matched case-control study to compare the effect of antecedent treatment with various antibiotics on subsequent isolation of vancomycin-resistant Enterococcus (VRE); 880 in-patients; 233 VRE cases, and 647 matched controls were included. After being matched for hospital location, calendar time, and duration of hospitalization, the following variables predicted VRE positivity: main admitting diagnosis; a coexisting condition (e.g., diabetes mellitus, organ transplant, or hepatobiliary disease); and infection or colonization with methicillin-resistant Staphylococcus aureus or Clostridium difficile within the past year (independent of vancomycin treatment). After controlling for these variables, we examined the effect of various antibiotics. Intravenous treatment with third-generation cephalosporins, metronidazole, and fluoroquinolones was positively associated with VRE. In our institution, when we adjusted the data for temporo-spatial factors, patient characteristics, and hospital events, treatment with third-generation cephalosporins, metronidazole, and fluoroquinolones was identified as a risk factor for VRE. Vancomycin was not a risk factor for isolation of VRE.
我们进行了一项配对病例对照研究,以比较先前使用各种抗生素治疗对随后分离出耐万古霉素肠球菌(VRE)的影响;纳入了880名住院患者,其中233例VRE病例和647例配对对照。在对医院位置、日历时间和住院时间进行匹配后,以下变量可预测VRE阳性:主要入院诊断;并存疾病(如糖尿病、器官移植或肝胆疾病);以及过去一年内耐甲氧西林金黄色葡萄球菌或艰难梭菌感染或定植(与万古霉素治疗无关)。在控制这些变量后,我们研究了各种抗生素的影响。静脉使用第三代头孢菌素、甲硝唑和氟喹诺酮与VRE呈正相关。在我们机构,当我们对时空因素、患者特征和医院事件的数据进行调整后,使用第三代头孢菌素、甲硝唑和氟喹诺酮治疗被确定为VRE的一个危险因素。万古霉素不是分离出VRE的危险因素。